UCB (WBO:UCB) YoY EPS Growth : 77.78% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is UCB YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. UCB's YoY EPS Growth for the quarter that ended in Dec. 2023 was 77.78%.

UCB's Earnings per Share (Diluted) for the six months ended in Dec. 2023 was €0.16.

UCB YoY EPS Growth Historical Data

The historical data trend for UCB's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB YoY EPS Growth Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EPS Growth

Get a 7-Day Free Trial

-3.30

-54.02

44.56

-60.73

-17.76

UCB Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY EPS Growth	Get a 7-Day Free Trial															31.41	-30.27	-96.41	-21.95	77.78

UCB YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

UCB's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EPS Growth (A: Dec. 2023 )
=	(Earnings per Share (Diluted) (A: Dec. 2023 )	-	Earnings per Share (Diluted) (A: Dec. 2022 ))	/	\| Earnings per Share (Diluted) (A: Dec. 2022 ) \|
=	(1.76	-	2.14)	/	\| 2.14 \|
=	-17.76 %

UCB's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EPS Growth (Q: Dec. 2023 )
=	(Earnings per Share (Diluted) (Q: Dec. 2023 )	-	Earnings per Share (Diluted) (Q: Dec. 2022 ))	/	\| Earnings per Share (Diluted) (Q: Dec. 2022 )) \|
=	(0.16	-	0.09)	/	\| 0.09 \|
=	77.78 %

UCB YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of UCB's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB (WBO:UCB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (WBO:UCB) » Definitions » YoY EPS Growth

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UNC:Germany UCB:Belgium

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB (WBO:UCB) Headlines

No Headlines